Treatment Clinical Trials for Mesothelioma

Clinical trials are research studies that involve people. The clinical trials on this list are for mesothelioma treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 55
1 2 3 Next >

  • Nivolumab and Ipilimumab in Treating Patients with Rare Tumors

    This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial enrolls participants for the following cohorts based on condition: 1. Epithelial tumors of nasal cavity, sinuses, nasopharynx: A) Squamous cell carcinoma with variants of nasal cavity, sinuses, and nasopharynx and trachea (excluding laryngeal, nasopharyngeal cancer [NPC], and squamous cell carcinoma of the head and neck [SCCHN]) B) Adenocarcinoma and variants of nasal cavity, sinuses, and nasopharynx (closed to accrual 07 / 27 / 2018) 2. Epithelial tumors of major salivary glands (closed to accrual 03 / 20 / 2018) 3. Salivary gland type tumors of head and neck, lip, esophagus, stomach, trachea and lung, breast and other location (closed to accrual) 4. Undifferentiated carcinoma of gastrointestinal (GI) tract 5. Adenocarcinoma with variants of small intestine (closed to accrual 05 / 10 / 2018) 6. Squamous cell carcinoma with variants of GI tract (stomach small intestine, colon, rectum, pancreas) (closed to accrual 10 / 17 / 2018) 7. Fibromixoma and low grade mucinous adenocarcinoma (pseudomixoma peritonei) of the appendix and ovary (closed to accrual 03 / 20 / 2018) 8. Rare pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma. Pancreatic adenocarcinoma is not eligible 9. Intrahepatic cholangiocarcinoma (closed to accrual 03 / 20 / 2018) 10. Extrahepatic cholangiocarcinoma and bile duct tumors (closed to accrual 03 / 20 / 2018) 11. Sarcomatoid carcinoma of lung 12. Bronchoalveolar carcinoma lung. This condition is now also referred to as adenocarcinoma in situ, minimally invasive adenocarcinoma, lepidic predominant adenocarcinoma, or invasive mucinous adenocarcinoma 13. Non-epithelial tumors of the ovary: A) Germ cell tumor of ovary B) Mullerian mixed tumor and adenosarcoma (closed to accrual 03 / 30 / 2018) 14. Trophoblastic tumor: A) Choriocarcinoma (closed to accrual) 15. Transitional cell carcinoma other than that of the renal, pelvis, ureter, or bladder (closed to accrual) 16. Cell tumor of the testes and extragonadal germ tumors: A) Seminoma and testicular sex cord cancer B) Non-seminomatous tumor C) Teratoma with malignant transformation (closed to accrual) 17. Epithelial tumors of penis - squamous adenocarcinoma cell carcinoma with variants of penis 18. Squamous cell carcinoma variants of the genitourinary (GU) system 19. Spindle cell carcinoma of kidney, pelvis, ureter 20. Adenocarcinoma with variants of GU system (excluding prostate cancer) (closed to accrual 07 / 27 / 2018) 21. Odontogenic malignant tumors 22. Pancreatic neuroendocrine tumor (PNET) (formerly named: Endocrine carcinoma of pancreas and digestive tract.) (closed to accrual) 23. Neuroendocrine carcinoma including carcinoid of the lung (closed to accrual 12 / 19 / 2017) 24. Pheochromocytoma, malignant (closed to accrual) 25. Paraganglioma (closed to accrual 11 / 29 / 2018) 26. Carcinomas of pituitary gland, thyroid gland parathyroid gland and adrenal cortex (closed to accrual) 27. Desmoid tumors 28. Peripheral nerve sheath tumors and NF1-related tumors (closed to accrual 09 / 19 / 2018) 29. Malignant giant cell tumors 30. Chordoma (closed to accrual 11 / 29 / 2018) 31. Adrenal cortical tumors (closed to accrual 06 / 27 / 2018) 32. Tumor of unknown primary (Cancer of Unknown Primary; CuP) (closed to accrual 12 / 22 / 2017) 33. Not Otherwise Categorized (NOC) Rare Tumors [To obtain permission to enroll in the NOC cohort, contact: S1609SC@swog.org] (closed to accrual 03 / 15 / 2019) 34. Adenoid cystic carcinoma (closed to accrual 02 / 06 / 2018) 35. Vulvar cancer (temporarily closed to accrual) 36. MetaPLASTIC carcinoma (of the breast) (closed to accrual) 37. Gastrointestinal stromal tumor (GIST) (closed to accrual 09 / 26 / 2018) 38. Perivascular epithelioid cell tumor (PEComa) 39. Apocrine tumors / extramammary Paget’s disease (closed to accrual) 40. Peritoneal mesothelioma (temporarily closed to accrual 05 / 08 / 2020) 41. Basal cell carcinoma (temporarily closed to accrual 04 / 29 / 2020) 42. Clear cell cervical cancer 43. Esthenioneuroblastoma (closed to accrual) 44. Endometrial carcinosarcoma (malignant mixed Mullerian tumors) (closed to accrual) 45. Clear cell ovarian cancer (closed to accrual) 46. Gestational trophoblastic disease (GTD) 47. Gallbladder cancer 48. Small cell carcinoma of the ovary, hypercalcemic type 49. PD-L1 amplified tumors 50. Angiosarcoma 51. High-grade neuroendocrine carcinoma (pancreatic neuroendocrine tumor [PNET] should be enrolled in Cohort 22; prostatic neuroendocrine carcinomas should be enrolled into Cohort 52). Small cell lung cancer is not eligible (temporarily closed to accrual 03 / 25 / 2020) 52. Treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC)
    Location: 891 locations

  • Pembrolizumab with or without Anetumab Ravtansine in Treating Patients with Mesothelin-Positive Pleural Mesothelioma

    This randomized phase I / II trial studies the side effects and how well pembrolizumab with or without anetumab ravtansine work in treating patients with mesothelin-positive pleural mesothelioma. Monoclonal antibodies, such as anetumab ravtansine and pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
    Location: 23 locations

  • A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

    This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD / RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.
    Location: 15 locations

  • Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma

    This trial studies how well the addition of targeted radiation therapy to surgery and the usual chemotherapy treatment works for the treatment of stage I-IIIA malignant pleural mesothelioma. Targeted radiation therapy such as intensity-modulated radiation therapy or pencil beam scanning uses high energy rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as pemetrexed, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving targeted radiation therapy in addition to surgery and chemotherapy may work better than surgery and chemotherapy alone for the treatment of malignant pleural mesothelioma.
    Location: 13 locations

  • Surgery, Chemotherapy, and Intensity Modulated Radiation Therapy in Treating Patients with Stage I-III Pleural Mesothelioma

    This phase II trial studies the side effects of surgery, chemotherapy, and intensity modulated radiation therapy in treating patients with stage I-III pleural mesothelioma. Drugs used in chemotherapy, such as pemetrexed disodium, cisplatin, and carboplatin, work in different ways to stop the growth of cancer, either by killing the cancer cells, by stopping them from dividing, or by stopping them from spreading. Intensity modulated radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy before radiation therapy may help kill more tumor cells after surgery.
    Location: 11 locations

  • Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma

    This study will evaluate intrapleural administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in combination with Celecoxib and Gemcitabine in patients with histologically confirmed Malignant Pleural Mesothelioma (MPM) who have failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, 1 of which must have been an anti-folate and platinum combination regimen. Eligible patients will be randomized 1:1 to either: 1. Treatment group: rAd-IFN + Celecoxib followed by Gemcitabine 2. Control group: Celecoxib followed by Gemcitabine Patients randomized to the treatment group will receive rAd-IFN administered into the pleural space via an Intrapleural catheter (IPC) or similar intrapleural device on study Day 1. The primary objective of this study is to compare the overall survival (OS) associated with rAd IFN, when administered with celecoxib and gemcitabine, versus that associated with celecoxib and gemcitabine alone for the treatment of patients with MPM
    Location: 11 locations

  • Ph 2 / 3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

    This is a study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme versus placebo in patients with malignant pleural mesothelioma. Malignant pleural mesothelioma have been found to require arginine, an amino acid. Thus the hypothesis is that by restricting arginine with ADI-PEG 20, the malignant pleural mesothelioma cells will starve and die.
    Location: 8 locations

  • Pevonedistat with or without Pemetrexed Disodium and Cisplatin in Treating Patients with Malignant Mesothelioma

    This phase I / II trial studies the side effects and best dose of pevonedistat with or without pemetrexed disodium and cisplatin, and to see how well they work in treating patients with malignant mesothelioma. Pevonedistat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pevonedistat, pemetrexed disodium, and cisplatin may work better in treating patients with malignant mesothelioma.
    Location: 7 locations

  • Nivolumab and Combination Chemotherapy before Surgery for the Treatment of Resectable Pleural Malignant Mesothelioma

    This phase I trial studies how well nivolumab and combination chemotherapy before surgery work in treating patients with pleural malignant mesothelioma that can be removed by surgery (resectable). Nivolumab is a type of medication called an antibody, which is like the proteins made by the immune system to protect the body from harm. Nivolumab blocks the protein PD 1 (programmed cell death receptor 1) that usually acts as a “brake” on the immune system. Blocking this protein is like releasing the brakes, so that the immune system can target cancer cells and destroy them. Drugs used in chemotherapy, such as pemetrexed, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab and combination chemotherapy may work better in treating patients with pleural malignant mesothelioma compared to combination chemotherapy alone.
    Location: 7 locations

  • Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158 / KEYNOTE-158)

    In this study, participants with multiple types of advanced (unresectable and / or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).
    Location: 7 locations

  • Mesothelin-Specific Genetically Engineered Lymphocytes with or without Cyclophosphamide and Pembrolizumab in Treating Patients with Malignant Pleural Disease

    This phase I / II trial studies the side effects and best dose of mesothelin-specific chimeric antigen receptor-engineered peripheral blood lymphocytes and to see how well it works with or without cyclophosphamide and pembrolizumab in treating patients with a malignant disease found in the thin layer of tissue that covers the lungs and lines the interior wall of the chest cavity (pleura), including malignant pleural mesothelioma, or previously treated non-small cell lung cancer or breast cancer that has spread to the pleura. Placing a gene that has been created in the laboratory into white blood cells (lymphocytes) may help the body build an immune response to kill tumor cells expressing the protein mesothelin. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving mesothelin-specific chimeric antigen receptor-engineered peripheral blood lymphocytes with or without cyclophosphamide may be a better treatment for malignant pleural disease.
    Location: 7 locations

  • AO-176 in Multiple Solid Tumor Malignancies

    This is a first-in-human, Phase 1 / 2 multi-center, open-label, dose escalation and expansion study of AO-176 which will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and clinical effects of AO-176 in patients with advanced solid tumors.
    Location: 6 locations

  • Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

    GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody intended for the treatment of cancers of different histology. This is a first-time-in-human (FTIH), open-label, multicenter study designed to investigate the safety, pharmacology, and preliminary antitumor activity in participants with selected, advanced or recurrent solid tumors with the aim to establish recommended dose(s) of GSK3359609 for further exploration as monotherapy and in combination with pembrolizumab, chemotherapy or other immune therapies. The study is comprised of two primary parts, each composed of two phases: Part 1: GSK3359609 monotherapy with Part 1A as dose escalation phase and Part 1B as cohort expansion phase; Part 2: GSK3359609 combination therapy with Part 2A pembrolizumab or GSK3174998 or dostarlimab or dostarlimab plus cobolimab or Bintrafusp alfa combination dose escalation phase and Part 2B expansion phase with pembrolizumab. Part 2A GSK3359609 combinations with chemotherapy will only consist of safety run-in cohorts. Each part and phase of the study includes a screening period, a treatment period, and a follow-up period. The primary objective of the study is to determine the safety, tolerability, maximum tolerated dose or the maximum administered dose of GSK3359609 alone or in combination.
    Location: 6 locations

  • A Vaccine (Galinpepimut-S) with Nivolumab for the Treatment of Patients with WT1-Expressing Malignant Pleural Mesothelioma

    This phase I trial studies the side effects of a vaccine, galinpepimut-S, and nivolumab in treating patients with WT1 positive malignant pleural mesothelioma. Vaccines, such as galinpepimut-S, are made from Wilms Tumor Protein 1 (WT1) peptide and may help the body build an effective immune response to kill tumor cells that express WT1. Galinpepimut-S is mixed with a substance called montanide, which helps to boost the immune reaction to galinpepimut-S. The mixture of the galinpepimut-S and montanide make up the actual final vaccine that is then given to patients. Immunotherapy with monoclonal antibodies, such as nivolumab, may remove signals that block the immune system’s activity, indirectly strengthening the immune system to help fight the cancer. It has been shown that cancer vaccines can sometimes increase these signals that actually block the immune system’s anti-cancer activity. Using a cancer vaccine (galinpepimut-S) directed to mesothelioma cells with a drug that can unblock these negative signals (nivolumab) may help treat malignant pleural mesothelioma.
    Location: 6 locations

  • Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression

    An open-label, Phase 1 / 2a study of HPN536 as monotherapy to assess the safety, tolerability and PK in patients with advanced cancers associated with mesothelin expression.
    Location: 7 locations

  • Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

    This is a first-in-human, open-label, non-randomized, two-part phase 1 trial of INBRX-109, which is a recombinant humanized multivalent antibody targeting the human death receptor 5 (DR5).
    Location: 5 locations

  • A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

    This is an open-label Phase 1b / 2 multicenter study of rebastinib (DCC-2036) in combination with carboplatin designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in patients with advanced or metastatic solid tumors.
    Location: 6 locations

  • Minimally-Invasive Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in Treating Patients with Low-Volume Peritoneal Carcinomatosis

    This phase I trial studies a minimally-invasive cytoreduction and hyperthermic intraperitoneal chemotherapy in treating patients with a small amount (low-volume) of peritoneal carcinomatosis, which is a term used to describe the widespread of cancerous tumors in the peritoneal cavity. Minimally-invasive cytoreduction is a less invasive type of surgery for peritoneal carcinomatosis and may have fewer side effects and improve recovery. Drugs used in chemotherapy, such as mitomycin C, cisplatin, and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Heating a chemotherapy solution and infusing it directly into the abdomen may kill more tumor cells. Giving minimally-invasive cytoreduction with hyperthermic intraperitoneal chemotherapy may work better in treating peritoneal carcinomatosis.
    Location: 4 locations

  • A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

    The primary purpose of this Phase 1, open-label study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-368 as a monotherapy and in combination with ABBV-181 in participants with locally advanced or metastatic solid tumors. The study will consist of 3 parts: ABBV-368 dose escalation, ABBV-368 tumor-specific dose expansion (triple negative breast cancer [TNBC] cohort and head and neck cancer cohort) and 18F-AraG Imaging Substudy.
    Location: 4 locations

  • Phase 1 / 2 Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer

    TC-210 T cells are a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex. This Phase 1 / 2 study aims to establish the recommended Phase 2 dose (RP2D) and subsequently determine an overall response rate in patients with advanced mesothelin-expressing cancers.
    Location: 5 locations

  • Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

    This study will evaluate the combination of Nivolumab and Ramucirumab in patients with previously-treated mesothelioma.
    Location: 3 locations

  • Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study

    This study will provide continuing availability to tazemetostat as a single agent to subjects who have completed their participation in an antecedent tazemetostat study (either with monotherapy or combination therapy). In addition, long-term safety and overall survival will be collected.
    Location: 2 locations

  • A Study of SGN-CD228A in Advanced Solid Tumors

    This trial will study SGN-CD228A to find out whether it is an effective treatment for different kinds of cancer. It will also look at what side effects (unwanted effects) may occur. The study will have two parts. Part 1 of the study will find out how much SGN-CD228A should be given for treatment and how often. Part 2 of the study will use the dose found in Part 1 and look at how safe and effective the treatment is.
    Location: 3 locations

  • Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma

    This is a phase 1 dose escalation study to characterize the feasibility, safety and tolerability of MCY-M11 when administered as an intraperitoneal (IP) infusion for 3 weekly doses for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, and subjects with peritoneal mesothelioma with recurrence after prior chemotherapy. The study will also assess multiple cycles of treatment and adding preconditioning with cyclophosphamide.
    Location: 2 locations

  • CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors

    This is a multicenter, open-label, phase 1b study of CBP501 / cisplatin / nivolumab combination administered once every 21 days to patients with advanced solid tumors.
    Location: 2 locations


1 2 3 Next >